Best responses to combination treatment
| . | . | . | . | . | Relapsed after lenalidomide . | Refractory to lenalidomide . | Refractory to both lenalidomide and bortezomib . |
|---|---|---|---|---|---|---|---|
| . | 1 mg (N = 4) . | 1.5 mg (N = 4) . | 2 mg (N = 4) . | 2.5 mg (N = 55) . | 2.5 mg (N = 18) . | 2.5 mg (N = 37) . | 2.5 mg (N = 16) . |
| Response | |||||||
| Complete or partial | 1 (25%) | 2 (50%) | 2 (50%) | 28 (51%) | 11 (61%) | 17 (46%) | 8 (50%) |
| Complete response | — | — | — | 3 | 1 | 2 | 2 |
| Very good partial response | — | — | — | 10 | 6 | 4 | 1 |
| Partial response | 1 | 2 | 2 | 15 | 4 | 11 | 5 |
| Minimal response | 1 | — | 1 | 11 | 2 | 9 | 5 |
| Stable disease | 1 | 1 | 1 | 15 | 5 | 10 | 3 |
| Progressive disease | 1 | 1 | — | 1 | 0 | 1 | — |
| . | . | . | . | . | Relapsed after lenalidomide . | Refractory to lenalidomide . | Refractory to both lenalidomide and bortezomib . |
|---|---|---|---|---|---|---|---|
| . | 1 mg (N = 4) . | 1.5 mg (N = 4) . | 2 mg (N = 4) . | 2.5 mg (N = 55) . | 2.5 mg (N = 18) . | 2.5 mg (N = 37) . | 2.5 mg (N = 16) . |
| Response | |||||||
| Complete or partial | 1 (25%) | 2 (50%) | 2 (50%) | 28 (51%) | 11 (61%) | 17 (46%) | 8 (50%) |
| Complete response | — | — | — | 3 | 1 | 2 | 2 |
| Very good partial response | — | — | — | 10 | 6 | 4 | 1 |
| Partial response | 1 | 2 | 2 | 15 | 4 | 11 | 5 |
| Minimal response | 1 | — | 1 | 11 | 2 | 9 | 5 |
| Stable disease | 1 | 1 | 1 | 15 | 5 | 10 | 3 |
| Progressive disease | 1 | 1 | — | 1 | 0 | 1 | — |